Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells

YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway

(2019) Hui Tong et al.   Drug Design Development and Therapy

Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response

(2019) Mahmoud Toulany   Genes

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT

(2018) Corinna Kosnopfel et al.   MOLECULAR CANCER RESEARCH

Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway

(2018) Po-Chen Chu et al.   ONCOGENE

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells

(2018) Eun-Ji Kim et al.   Oncotarget

Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase

(2018) Aadhya Tiwari et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma

(2018) Chen Liang et al.   CANCER SCIENCE

Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer

(2017) Takahisa Yamashita et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells

(2017) Hong Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma

(2017) Tao Guo et al.   Oncotarget

Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target

(2017) Pramod Kumar Maurya et al.   Journal of Cancer

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer

(2017) Asmus Heumann et al.   Scientific Reports

Y-box-binding protein 1 as a non-canonical factor of base excision repair

(2016) Elizaveta E. Alemasova et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Uncoupling of EGFR–RAS signaling and nuclear localization of YBX1 in colorectal cancer

(2016) F Roßner et al.   Oncogenesis

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

(2015) S. Napolitano et al.   CLINICAL CANCER RESEARCH

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

(2015) Patricia Alamo et al.   FASEB JOURNAL

Metastatic Colorectal Cancer: Current State and Future Directions

(2015) Marwan G. Fakih   JOURNAL OF CLINICAL ONCOLOGY

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

(2015) J Cisowski et al.   ONCOGENE

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

(2015) Mahmoud Toulany et al.   SEMINARS IN CANCER BIOLOGY

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells

(2015) Alastair H. Davies et al.   Oncotarget

Colorectal cancer

(2015) Ernst J. Kuipers et al.   Nature Reviews Disease Primers

The Expression Level and Prognostic Value of Y-Box Binding Protein-1 in Rectal Cancer

(2015) Yu Zhang et al.   PLoS One

Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway

(2014) B Zhang et al.   BRITISH JOURNAL OF CANCER

Y-box binding protein 1 – A prognostic marker and target in tumour therapy

(2014) Corinna Kosnopfel et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers

(2014) Ida Aronchik et al.   MOLECULAR CANCER RESEARCH

YB-1: oncoprotein, prognostic marker and therapeutic target?

(2013) Annette Lasham et al.   BIOCHEMICAL JOURNAL

The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress

(2013) Ekaterina R Kim et al.   CELL CYCLE

YB-1 disrupts mismatch repair complex formation, interferes with MutSα recruitment on mismatch and inhibits mismatch repair through interacting with PCNA

(2013) Y-W Chang et al.   ONCOGENE

YB-1 protein: functions and regulation

(2013) Dmitry N. Lyabin et al.   Wiley Interdisciplinary Reviews-RNA

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers

(2012) Anna L. Stratford et al.   STEM CELLS

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

(2012) Jae-Kyung Won et al.   Journal of Molecular Cell Biology

EGFR-targeted therapy

(2011) Loredana Vecchione et al.   EXPERIMENTAL CELL RESEARCH

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Metastatic Colorectal Cancer: From Improved Survival to Potential Cure

(2010) David J. Gallagher et al.   ONCOLOGY

Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases

(2010) A. Moritz et al.   Science Signaling

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Participation of DNA repair in the response to 5-fluorouracil

(2008) M. D. Wyatt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE